PRESS RELEASE published on 11/19/2024 at 07:30, 1 year 11 months ago Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial Nicox announces the publication of the adaptive design period of the NCX 470 Mont Blanc Phase 3 trial, selecting 0.1% concentration due to better intraocular pressure reduction and safety profile Phase 3 Trial Ophthalmology Nicox NCX 470 Adaptive Design
BRIEF published on 10/14/2024 at 07:35, 2 years ago Nicox and Soleus sign $16.5 million financing agreement Funding Nicox NCX 470 Soleus Capital VYZULTA
PRESS RELEASE published on 10/14/2024 at 07:30, 2 years ago Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Nicox and Soleus sign $16.5 million royalty and equity financing agreement, reducing debt burden and financing into Q3 2025. Topline results expected in Q3 2025 for NCX 470 Denali Phase 3 trial Equity Financing Nicox NCX 470 Soleus Royalty
BRIEF published on 09/18/2024 at 07:35, 2 years 1 month ago Nicox Announces Approval of ZERVIATE in China China Ophthalmology Nicox ZERVIATE Ocumension
PRESS RELEASE published on 09/18/2024 at 07:30, 2 years 1 month ago Nicox Announces Approval of ZERVIATE in China Nicox announces approval of ZERVIATE in China by partner Ocumension Therapeutics for ocular itching, adding royalty revenue stream. Launch expected to boost market penetration China Approval Nicox ZERVIATE Ocular Itching
BRIEF published on 09/04/2024 at 07:35, 2 years 2 months ago Nicox Appoints Christine Placet as Director; Michele Garufi Retires from Board of Directors Board Of Directors Ophthalmology Christine Placet Nicox Michele Garufi
PRESS RELEASE published on 09/04/2024 at 07:30, 2 years 2 months ago Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Nicox appoints Christine Placet to Board of Directors as Michele Garufi steps down after over 25 years. Entire Nicox Board renewed for strategic direction support Board Of Directors Biotech Industry Christine Placet Nicox Michele Garufi
BRIEF published on 07/19/2024 at 07:35, 2 years 3 months ago Nicox: Participation in upcoming conferences Conférences 2024 Investments Ophthalmology Nicox
PRESS RELEASE published on 07/19/2024 at 07:30, 2 years 3 months ago Nicox announces attendance at upcoming conferences Nicox announces attendance at upcoming international conferences, including H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and AAO 2024 Clinical Development International Conférences Ophthalmology Nicox
BRIEF published on 07/18/2024 at 07:35, 2 years 3 months ago Nicox Provides Second Quarter 2024 Update Q2 2024 Financial Update Ophthalmology Nicox NCX 470
Published on 11/06/2026 at 22:15, 10 hours 47 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 20 hours 2 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 20 hours 32 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 20 hours 32 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 12 hours 46 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 13 hours 46 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 14 hours 1 minute ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 14 hours 29 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 15 hours 1 minute ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 15 hours 2 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 15 hours 7 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 15 hours 27 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
